Skip to content
value.today

Rezo Therapeutics, Inc.

Total raised
$68 M
1 round on record
Latest round
$68 M
Jul 2022
First round on record
Jul 2022
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Rezo Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2022$68 MNo. 1$50 to $250 million

Rezo Therapeutics, Inc.: Raise no. 1, Jul 2022

Investors in this round

21 investors had bought by the notice of Aug 18, 2025: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$68 M of $80 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Derek Hicks · Executive Officer, Director
  • Jennifer Chang · Executive Officer
  • Nevan Krogan · Executive Officer, Director
  • George Scangos · Director
  • Norbert Bischofberger · Director
  • Simeon George · Director
  • Tiba Aynechi · Director
  • Vineeta Agarwala · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “This filing covers the sale and purchase of Series A Preferred Stock, and the Common Stock issuable upon conversion thereof.”

Signed by Jennifer Chang, Secretary. Newest notice filed Aug 18, 2025 (2 amendments). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Rezo Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2025).

    SEC Form D · Aug 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2025

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Rezo Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Rezo Therapeutics, Inc.
NameRoleNamed in
Derek HicksExecutive officerAug 2025
Jennifer ChangExecutive officerAug 2025
Nevan KroganExecutive officerAug 2025
Nadir MahmoodExecutive officerDec 2023
Sourav BandyopadhyayExecutive officerDec 2022
Derek HicksDirectorAug 2025
George ScangosDirectorAug 2025
Nevan KroganDirectorAug 2025
Norbert BischofbergerDirectorAug 2025
Simeon GeorgeDirectorAug 2025
Tiba AynechiDirectorAug 2025
Vineeta AgarwalaDirectorAug 2025
Nadir MahmoodDirectorDec 2023
Nadir MahmoodPromoterDec 2023
Nevan KroganPromoterDec 2022
Sourav BandyopadhyayPromoterDec 2022